A Low Dose of Hydrous Icaritin Nano-Formulation with Remarkable Efficacy and Tumor Targeting in Cancer Therapy.

Abstract

Background: The use of chemotherapeutic drugs is restricted in the tumor-therapy because of the severely toxic and side effects among most important factors. The active herbal extracts are always used as a high dose while in the tumortherapy to achieve good anti-tumor effects. Hydrous icaritin has a high activity while there are few existing dosage forms as a result of low solubility in water and poor bioavailability. Results: The prepared hydrous icaritin nanorods (DP-HICT NRs) using mPEG2000-DSPE as a stabilizer, presented a narrow distribution of particle size with of 217 nm and a properly high drug-loading content of approximately 65.3±1.5%. A low dose of hydrous icaritin nano-formulation shows remarkable efficacy in cancer therapy (tumor inhibition rate: 61.36±10.80%) compared with the same dose of Paclitaxel injection (tumor inhibition rate: 66.80±4.43%), which approved as medicaments. Not only that, DP-HICT NRs can escape the clearance of the immune system and enhance targeting ability to the tumor site with only one excipient and such a low dose. Conclusions: This kind of nanoparticles contain a low dose of HICT used mPEG2000-DSPE as a stabilizer, while can achieve good tumor targeting as some active targeting agents and an anti-tumor effect as the PTX injection. There are broad prospects in drug safety, anti-tumor efficacy and even prognosis.

• Authors: Jingxin Fu, Yian Wang, Haowen Li, Likang Lu, Hui Ao, Meihua Han, Yifei Guo, Xiangtao Wang
• Journal: Journal of biomedical nanotechnology (J Biomed Nanotechnol) Vol. 17 Issue 10 Pg. 2003-2013 (Oct 01 2021) ISSN: 1550-7033 [Print] United States
• PMID: 34706800 (Publication Type: Journal Article)

Chemical References

• Flavonoids
• Paclitaxel
• icaritin

Topics

• Cell Line, Tumor
• Flavonoids
• Humans
• Nanoparticles
• Neoplasms (drug therapy)
• Paclitaxel
• Particle Size